| Autor: |
Rasekh EO; Clinical Pathology Department, National Cancer Institute, Cairo University, Foum elkhalig Sq., Cairo, Egypt., Osman R; Clinical Pathology Department, National Cancer Institute, Cairo University, Foum elkhalig Sq., Cairo, Egypt., Ibraheem D; Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt., Madney Y; Paediatric Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt., Radwan E; Clinical Pathology Department, National Cancer Institute, Cairo University, Foum elkhalig Sq., Cairo, Egypt., Gameel A; Clinical Pathology Department, National Cancer Institute, Cairo University, Foum elkhalig Sq., Cairo, Egypt., Abdelhafiz A; Clinical Pathology Department, National Cancer Institute, Cairo University, Foum elkhalig Sq., Cairo, Egypt., Kamel A; Clinical Pathology Department, National Cancer Institute, Cairo University, Foum elkhalig Sq., Cairo, Egypt., Elfishawi S; Clinical Pathology Department, National Cancer Institute, Cairo University, Foum elkhalig Sq., Cairo, Egypt. Sally.elfishawi@nci.cu.edu.eg. |
| Abstrakt: |
Mixed phenotype acute leukemia (MPAL) is a rare type of leukemia with a limited number of studies conducted to characterize its clinical spectrum and most importantly the best treatment modality. MPAL blasts show more than one phenotype either myeloid/monocytic with T- or B-lymphoid or extremely rare triple lineage associated phenotypic markers. This study aimed to characterize MPAL cases with special emphasis on comparing adult and pediatric age groups, exploring treatment regimens, and clinical outcome. Among 2571 acute leukemia patients, 102 MPAL cases fulfilling the 2008/2016 WHO diagnostic criteria of MPAL were recruited in the study. The incidence of MPAL was 4% of acute leukemia patients. Pediatric cases were 54 (53%) while adults were 48/102 (47%). Myeloid/B-lymphoid phenotype was found in 86/102 (84%), with BCR-ABL fusion gene transcript detected in 14/102(13.7%) patients. ALL-like treatment showed better response rates as compared with the myeloid based regimen (p = 0.001). MPAL behaves in a manner that resembles in clinical features, their lymphoid progenitor counterpart leukemias both in adults and pediatric patients with superior treatment response to ALL-like regimen, especially in adults. |
Full text from SpringerLink